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ABSTRACT 
 
Background:  To describe the relative frequency and distribution of neonatal 
tumours; to determine the age at presentation to the oncology unit and to determine 
the extent of the delay in referral. To describe any associated syndromes in individual 
malignancies. 
Material and methods:  A retrospective case series was performed covering 24 
years.  Demographics, means of diagnosis, treatment and outcome details were 
reviewed. 
Results:  There were a total of 2626 patients that presented to the oncology 
department with suspected malignancies.  Out of that, 2308 patients were diagnosed 
with a malignancy and 318 patients had benign tumours.  Over the 24 year period 117 
tumours were diagnosed in neonates (4,4%).  Due to incomplete data 29 patients were 
excluded.  Of the remaining patients, 61 were diagnosed with benign tumours and 27 
with malignant tumours. The male to female ratio was 1: 1,5.  The mean age at 
presentation was 16 days.  The mean age at diagnosis was 36 days.  Histology and 
radiology were diagnostic in 40,9% and 19,3% respectively. A combination of 
histology and radiology was used to make a diagnosis in 21,6% of patients, 11,4% of 
diagnoses were based on clinical examination and 6,8% on biochemistry and 
haematology.	   	   Malignant soft tissue tumours were the most common malignancy 
(25,9%) followed by renal tumours (18,5%), leukaemia (14,8%), neuroblastomas 
(11,1%) and retinoblastomas (11,1%).  Teratomas (45,9%) and benign vascular 
tumours (44,3%) were the most common benign tumours. Chemotherapy was used to 
treat 22 neonates, while 50 underwent surgical removal of the tumour.  Half (51,9%) 
of the patients diagnosed with a malignant tumour died, while 11,1% of patients were 
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lost to follow up.  Just under 10% (8,2%) of the patients diagnosed with a benign 
tumour died, while 44,3% of patients were lost to follow up.  The overall mortality 
amongst patients diagnosed with benign or malignant tumours was 21,6%.	  
Conclusion:  There is a much higher incidence of benign tumours diagnosed in 
neonates (69,3%) compared to older children (12,1%).  Only 1,2% of all childhood 
malignancies in our unit occurred in the neonatal period, which is slightly lower than 
the reported 2%.  Two of the major issues that need to be addressed in the future 
management of neonatal tumours are prompt referral for prompt diagnoses and better 
follow up.   
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1.0  INTRODUCTION 
 
A tumour is defined as a mass of new tissue which persists and grows independently 
of its surrounding structures and which has no physiological use.1  It can be classified 
as benign or malignant.  A benign tumour does not metastasize, invade or destroy 
adjacent normal tissue.2  A malignant tumour is one that invades surrounding tissues 
and is usually capable of producing metastases.2  It is likely to recur after attempted 
removal and can cause death of the host unless adequately treated.2   
 
Neonatal tumours occur within the first 28 days of life.3 These tumours are known to 
be very rare, with a prevalence of 1/12 500 to 1/17 300 total births.4,5,6  It has been 
predicted that most neonatal units will see one case every one to two years.4  The 
accuracy of this reported prevalence is unclear, as the majority of the studies reviewed 
were hospital based.6,7,8  An ideal study would be a population based study where the 
overall incidence can be determined irrespective of government and private 
facilities.3,6   A few studies considered stillborn babies and early neonatal deaths, 
however as postmortem examinations are not routinely performed in all institutions 
some tumours might be missed.  A study done in 1987 in Toronto, Canada reported 
that 41% of neonatal tumours were evident on the first day of life, however, in 17% 
the diagnosis was made on autopsy.6  The possibility of lab errors should also be 
taken into consideration due to the difficulty in distinguishing malignant tissue from 
normal neonatal tissue and it is reasonable to believe that the number of neonatal 
tumours are under reported.   Lastly most case series reviewed did not leave room for 
late presentations or delayed referrals and used four weeks as a cut off age for patients 
they included in their studies. 
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Classification 
Due to the uncommon behavior, neonatal tumours can be divided into four clinical 
groupings.3 
 
Table 1.  Tumour types.3 
1. Benign tumours a. Life threatening because of size 
and    location (e.g. cervical 
teratoma) 
b. Have a known tendency towards 
malignant transformation 
(sacrococcygeal teratoma, giant 
naevus) 
c. Benign tumours, not life 
threatening or tending towards 
malignant transformation 
(mesoblastic nephroma) 
 
2.  Tumours demonstrating local  
      invasiveness but no metastatic  
      potential 
(E.g. congenital fibrosarcoma, 
fibromatoses) 
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3. Malignant tumours a. Behave more like those occurring 
in older children 
b. Behave better than expected 
(hepatoblastoma, neuroblastoma) 
c. Behave worse than expected 
(congenital alveolar 
rhabdomyosarcoma, leukaemia) 
d. Demonstrate unpredictable or 
uncertain behavior 
4.  Extremely rare tumours Carcinoma, lymphoma, Hodgkins 
disease, Kaposi sarcoma 
 
 
Aetiology 
 
The aetiology of cancer in a child is multifactorial and includes both environmental 
factors and genetics.3 Neonates are characterized as a separate entity as the 
environmental interference is minimal.3 There are two groups of genetic abnormalities 
involved in the epidemiology of tumours in childhood. 
The first comprises the constitutional chromosomal abnormalities resulting in an 
increased risk of malignancy, for example retinoblastoma on chromosome 13q and 
rhabdomyosarcoma on chromosome 11p.9 Secondly, genetically determined 
syndromes, where an increased risk of malignancy exists.  For example familial 
retinoblastoma with the gene RB1 and Down syndrome, which has been proven to 
have an increased risk of leukaemia and germ-cell tumours.3   Other environmental 
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factors include ionizing radiation, infection or drugs taken during pregnancy.3 
Transplacental spread of maternal tumours have been reported with malignant 
melanoma, leukaemia and choriocarcinoma.5,6 
 
Demographics 
 
Gender predisposition seems to vary from study to study.  Some studies reported a 
male predominance, while other studies reported an equal male to female ratio except 
for teratomas, which showed a female predominance.6,3 
In the USA it was reported that Japanese children have the highest incidence of 
neonatal tumours while black African American children had the lowest reported 
cases.3 
 
Distribution 
 
The most common tumour in a neonate is a teratoma followed by benign vascular 
tumours.  The most common malignant tumours are neonatal neuroblastomas, 
malignant soft tissue tumours and retinoblastomas.6,7 
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1.1  Germ-cell tumours (GCT) 
 
Germ-cell tumours can be divided into seminoma/germinoma, embryonal carcinoma, 
yolk sac tumour, choriocaricnoma and mature or immature teratomas.10   Malignant 
germ-cell tumours are rare tumours and the incidence varies according to the age and 
sex of the patient.10 
 
TERATOMA: Teratomas are the most frequently diagnosed perinatal neoplasm 
accounting for one third of all cases.5   It is very rarely malignant and the 
sacrococcygeal region is the most common site.4,5  Teratomas can be classified into 
two groups according to histology, namely mature teratomas which are considered as 
benign tumours, and immature teratomas which may show clinical features of 
malignancy.10  Numerous studies have shown a female predominance in teratomas.11  
 
SACROCOCCYGEAL TERATOMA:  It is considered to be the most common 
tumour in the newborn period with a reported incidence of approximately one in 35 
000 – 40 000 live births.12   It is composed of two or three germ cell layers, has 
multiple tissue types and can present in various shapes and sizes.12   It is more 
common in females with a M: F ratio of 1: 3-4.12,13 
 
Sacrococcygeal teratomas can present either prenatally or postnatally.12,13  When the 
diagnosis is made before 30 weeks gestation there is a well documented association 
with high foetal morbidity and mortality.12 Patients with external sacrococcygeal 
teratomas usually present at birth with a protruding mass from the sacrum.13  The 
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overlying skin can have changes such as redundancy or patchy, dark discoloration, 
which can simulate a haemangioma or lymphangioma.11  
 
The preferred treatment includes complete surgical excision (including resection of 
the coccyx).12  The newborn with sacrococcygeal teratoma has an excellent prognosis 
depending on the timing of diagnosis, malignant potential of the tumour and the ease 
of surgical resection.12 Chemotherapy and radiotherapy are indicated in malignant 
cases.12   Strict follow up for the first three years of life is essential due to the high risk 
of recurrence early in life.12 
 
1.2 Benign vascular tumours 
 
The second most common tumours of infancy are benign vascular lesions.14,15  
Though histologically benign, certain unique presentations of vascular tumours may 
have serious consequences for the newborn.14 
 
HAEMANGIOMA:  Haemangiomas are one of the most common tumours of 
infancy with an incidence of 1 - 2,6% of all live births. 14 It is more common in the 
white population and an incidence as high as 10% has been recorded. 14 It is four 
times more common in female patients and is more commonly seen in premature 
babies. 14 Most infantile haemangiomas are benign and do not cause any morbidity or 
mortality. 15  Vascular neoplasms can incite a consumptive coagulopathy and may be 
life threatening (Kasabach-Merritt syndrome). 15 
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Haemangiomas generally cease growing by the time the infant is 18 months old.  
Slow spontaneous involution then occurs over the next two to six years. 14    Medical 
intervention is often required for large ulcerative haemangiomas or those impinging 
on vital structures. 14 
 
HAEMANGIOENDOTHELIOMA:  A haemangioendothelioma is a rare benign 
vascular tumour arising from mesenchymal tissue usually located in the liver. 16   
Neonates often present with cardiac failure because of extensive arteriovenous 
shunting within the lesion. 16   Spontaneous involution normally occurs in the first 12 - 
18 months of life thus asymptomatic lesions are generally managed conservatively. 16 
If an infant presents with cardiac failure or anaemia they are normally treated with 
corticosteroids or interferon alpha-2a, to slow down the tumour growth. 16 In severe 
cases surgical resection, partial hepatectomy and embolization of afferent vessels 
should be considered. 16 
 
1.3  Malignant Soft Tissue tumours 
 
The incidence of malignant soft tissue tumours varies greatly from study to study with 
an estimate of 10 – 30% of all neonatal malignancies.6,7,8,17 These tumours include 
fibrosarcomas, rhabdomyosarcomas, leiomyosarcomas, liposarcomas, haemangioperi-
cytomas and synovial sarcomas.4,5   
 
FIBROSARCOMA:  Infantile fibrosarcoma has an incidence of five per million 
infants.18   It occurs more in males than females with a M: F ratio of 1: 0,2.18   Most 
patients with infantile fibrosarcoma present with a tumour on the extremities, more 
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often the lower extremities than the upper extremities.4,18  Other presentations include 
tumours on the head and neck, abdomen and pelvis.18 
 
Fibrosarcomas are known to have an unpredictable clinical behavior.  They are very 
chemosensitive, and may undergo spontaneous regression.4,18,19  A Turkish study of 
12 neonates with fibrosarcoma, showed a mortality rate of just 8%.18 
 
RHABDOMYOSARCOMA (RMS):  Rhabdomyosarcoma is a malignant 
mesenchymal neoplasm that exhibits striated muscle differentiation.20 Two percent of 
all rhabdomyosarcomas are present at birth.20   A third of all rhabdomyosarcomas are 
associated with at least one congenital anomaly.21   In 20% of cases 
rhabdomyosarcoma presented on the extremities, more commonly the lower 
extremities than the upper extremities.21  Other sites included the head and neck and 
the genitourinary tract.20 
 
Optimal therapy has not been well established but neonatal rhabdomyosarcomas 
respond excellently to chemotherapy and surgery can even be avoided.21   The 
prognosis of neonates with rhabdomyosarcoma is largely affected by: the immaturity 
of organs resulting in organ insufficiency during chemotherapy, low immunity in the 
neonatal period, the presence or absence of distant metastases, site, surgical 
resectability, histology, pre-treatment staging and clinical group staging.21    
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1.4  Renal tumours 
 
Malignant neonatal renal tumours are very uncommon with an incidence of 4% of all 
neonatal malignancies.6,17  
 
CONGENITAL MESOBLASTIC NEPHROMA (CMN):  CMN is reported as the 
most common renal tumour in neonates with more than 80% of all CMN presenting in 
the neonatal period.22,23,24,25  There are two pathological subtypes including the classic 
CMN and the atypical or cellular CMN.23,24,25,26 About 10% of  cases diagnosed are of 
mixed histology with a classic and cellular picture.24  The natural histology of both 
variants are benign, but there have been reported cases of local recurrence and 
metastases.4,22 
 
There is a strong male predominance with M: F ratio of 2: 1.4,24   There is also a well 
documented association with mesoblastic nephroma and polyhydramnios.22,23,25 The 
most common presentation is an asymptomatic abdominal mass.22  The gold-standard 
imaging modality is MRI but it is limited in distinguishing between CMN and Wilms’ 
tumour.4 A histological diagnosis remains mandatory.4 
 
The prognosis for patients with CMN is very good and treatment normally involves 
surgery alone.24 In 95% of patients CMN’s are benign and no further treatment is 
required.31   The overall survival rate is reported to be as high as 95% - 98%.4  
Relapses were reported in 5% of patients, and are thought to be due  to incomplete 
resection, older age and the cellular subtype.22,24,26   
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WILMS’ TUMOUR (WT):  Wilms’ tumours normally present in an older age group 
but there have been reported cases of Wilms’ tumours diagnosed in the neonatal 
period.4 Unlike CMN, Wilms’ tumours are more often seen in females of African 
descent.4   Wilms’ tumours are also more commonly associated with congenital 
anomalies and some studies show an association with syndromes in as many as 25% 
of cases.4  
 
As for CMN, neonatal WT presents with a solid abdominal mass, which is difficult to 
distinguish from other renal tumours by radiological imaging alone.4   Histology 
remains diagnostic.4 Treatment for neonates with unilateral WT is a primary 
nephrectomy and the five year survival rate for neonatal WT has been reported to be 
around 90%.4  
 
1.5  Congenital/Neonatal Leukemia 
 
Congenital leukemia is very rare with a reported incidence of one in five million live 
births and represents approximately 8% of all neonatal malignancies.6, 27 Unlike the 
paediatric population where lymphoid lineages predominate, myeloid lineages are 
reported more often in the neonatal period.5,27,28,29   
 
The aetiology of congenital leukemia is unknown but it has been reported that 
maternal exposure to radiation, maternal dietary exposure to bioflavonoids, maternal 
use of tobacco and illicit drugs, and inherited conditions such as Down syndrome and 
Turner syndrome, increase the risk of congenital leukemia.5,27,28  It has been shown 
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that patients with Down syndrome have a 20-fold increased risk of developing 
leukaemia in their lifetime.30   
 
The criteria for diagnosing congenital leukaemia include: a) disease presentation 
within 30 days after birth, b) immature cell proliferation in myelomonocytic, 
lymphoid, or erythoid series, c) infiltration of these cells into extra hematopoietic 
tissue and d) the absence of any other conditions that mimics congenital leukaemia, 
together with the absence of transient abnormal myeloproliferative disorders typically 
seen in patients with Down syndrome.28,31 
 
Transient myeloproliferative disorder is characterized by proliferation of abnormal 
myeloblasts in bone marrow and blood of infants with Down syndrome. 32   It is very 
difficult to distinguish it from AML morphologically and it resolves spontaneously 
without therapy. 32   It manifests in the first few days of life where AML is generally 
present after one year of age. 32   There have, however, been reported cases of AML at 
a younger age, but it is very rare. 32 
 
Patients with leukaemia present with anaemia, thrombocytopenia, high white cell 
count and organomegaly.6,27,28,29  In 25% - 30% of cases, patients present with 
specific cutaneous infiltrates (leukemia cutis) which usually present as firm blue or 
red nodules (‘Blueberry Muffin’).27  The disease is not always apparent at birth and 
signs may be evident after days and weeks.  There may be an antecedent period of 
failure to thrive, diarrhoea and low grade fever.29  Many neonates however present in 
respiratory distress secondary to pulmonary leukostasis and bronchopneumonia.29,31 
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Diagnosis of congenital leukemia is made on peripheral blood and / or bone marrow 
smears together with standard immunophenotypic and cytogenetic investigations, 
where possible.33 The mainstay of treatment remains chemotherapy but unfortunately 
congenital leukemia has a very poor prognosis with 23% of patients surviving to the 
age of two years.27,29 
 
1.6  Neuroblastoma 
 
Neonatal neuroblastoma is the most common malignant tumour seen in the majority 
of studies, accounting for 30 – 50% of cases in most series. 3,4,5,6,7,34,35 
 
 It was proposed in one study that there is an increased incidence in males with a M: F 
ratio of 2: 1, but other studies failed to confirm this gender preference.  
 
 Ultrasound remains the investigation of choice, while CT Scans and MRI Scans are 
of value in diagnosing the presence of metastases.4  Urine catecholamine metabolites 
are considered as tumour markers, and vanillylmandelic acid (VMA) and 
homovanillic acid (HVA) are increased in 80% - 90% of neonates diagnosed with a 
neuroblastoma.4,34  Histopathology is required to confirm the diagnosis.34  Once the 
diagnosis is confirmed, the treatment will depend on the histology, cytogenetics and 
staging of the tumour. 34   Death resulting from tumour was seen in 23 – 34% of 
reported cases, while other studies showed spontaneous remission of stage 4S disease 
and an overall survival of 91%.34,35 
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1.7  Retinoblastoma 
 
Retinoblastoma is a highly malignant intraocular tumour requiring an early diagnosis 
and immediate treatment.36   The incidence is influenced by the policy of elective eye 
examination in children with a positive family history of retinoblastoma. 5   A series 
from Toronto, Canada reported an unusually high incidence of 25% of patients with 
neonatal retinoblastoma, which were diagnosed on elective eye examination because 
of high index of suspicion. 5,6,37  
 
It was shown in only one study that there appeared to be a female predominance in 
neonatal retinoblastoma with an M: F ratio of 1: 1,6.37   The presenting symptoms 
included leucocoria (56,2%), strabismus (23,6%), poor vision (7,7%), family history 
(6,8%), proptosis, failure to thrive and heterochromia iridis.6,37    Some studies 
revealed the majority of patients to have bilateral disease,5,6  while other studies 
reported a higher incidence of unilateral retinoblastoma.37,38  
 
The diagnosis is made by examining the fundus of the eye with indirect 
ophthalmoscopy.38  Fundus imaging, MRI and ultrasonography are used to support 
the diagnosis and stage the tumour.38  
 
Over the past five years, ophthalmic artery chemosurgery has been proven to be as 
effective as previous management with primary radiation or systemic chemotherapy, 
but without the unfortunate side effects.39  The mortality rate in one series was 24%, 
where four out of the 17 neonates with retinoblastomas who received treatment 
consisting of enucleation, radiochemotherapy or both, died.6
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1.8  Langerhans cell Histiocytosis (LCH) 
 
The incidence of neonatal LCH is estimated to be approximately one to two per 
million live births.40   A study from Chicago demonstrated a male predisposition 
where only six out of the 19 neonates investigated were female.41 
 
Neonates most commonly present with vesiculopustular lesions that can easily be 
mistaken for an infectious process.41 The clinical presentation can however vary from 
a single-organ to multiorgan invasion of the skin, bone, lymphatic system, liver, 
spleen, lungs and the central nervous system.40 It is, however, not possible to predict 
the extent of the systemic involvement based on the morphologic characteristics of 
the skin findings, therefore it is of great importance to perform a series of baseline 
studies when a diagnosis of LCH is suspected.41  
 
Treatment recommendations should be tailored according to the sites of 
involvement.41 The prognosis depends entirely on the organs involved and the 
response to chemotherapy.40 
 
1.9  Hepatic tumours 
 
Hepatic tumours comprise about 4% of all tumours occurring in the neonatal period.4   
There is a largely unexplained but clearly recognized predominance in white, male 
patients, in preterm infants and those with low birth weight.4  
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HEPATOBLASTOMA:  Hepatoblastoma is a very rare tumour and less than 10% of 
all hepatoblastoma cases are diagnosed in the neonatal period.42 There is a slight male 
predominance with a M: F ratio of 1,4 - 2: 1.42 A well documented association with 
hepatoblastoma and inherited syndromes include Hemi-Beckwith-Wiedemann 
syndrome and Intestinal Adenomatous Polyposis syndrome.4   
 
The most common presentation includes an upper quadrant abdominal mass and 
generalized abdominal distention.43 The first line of investigation is ultrasonography.4 
Approximately 90% of infants with hepatoblastomas will have an increased Alpha 
Feto Protein (AFP) level.4,42,43 
 
Preoperative chemotherapy is considered the treatment of choice, followed by 
surgery.4  The five-year survival rate in neonates diagnosed with hepatoblastoma is 
25%.4,7,8,17 
 
1.10 Central Nervous System tumours 
 
Congenital brain tumours are rare with an incidence of 1,1 – 3,6 per 100 000 
newborns.44 About 1% of all childhood brain tumours occur in the neonatal period, 
with a prevalence of 8% of all neonatal malignancies.5,6,45,46   
 
A study in Boston described medulloblastoma to be the most common CNS tumour 
seen in neonates, followed by ependymoma, astrocytoma and choroid plexus 
papilloma.47   Overall it was reported that there is a slight male predilection with a M: 
F ratio of 1: 0,7.46  
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Congenital brain tumours have the propensity to bleed and intramural hemorrhage 
occurs in 14% - 18% of cases. 46   A CT scan is very useful to detect hydrocephalus 
and associated hemorrhage.46 
  
MEDULLOBLASTOMA:  In 1984 there was a study conducted in Boston which 
described 55 infants and stillborn babies with central nervous system tumours.47   
Medulloblastoma was by far the most common, with a prevalence of 13 out of the 55 
patients, which accounted for 24% of all CNS tumours in the neonatal period.47 
Medulloblastoma is a malignant and invasive embryonal tumour of the cerebellum.45 
Common presenting features include increased head circumference, distended anterior 
fontanel and vomiting.48   
 
Although numerous recent publications show an improvement in treatment, the 
prognosis of neonatal medulloblastoma remains very poor with a mean survival of 
only 6,8 months.48 A combination of surgery, chemotherapy and radiation are 
regarded as the gold standard of treatment, but the controversy with radiating a 
developing brain persists, as the long term late effects can be devastating.48  
 
PRIMITIVE NEUROECTODERMAL TUMOURS (PNET):  Although PNET’s 
are relatively common in the first year of life they constituted only 3,4% - 13,2% of 
foetal CNS tumours.45   They are a heterogeneous group of highly malignant small-
cell tumours thought to derive from the neural crest.45 
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2.0  MATERIAL AND METHODS 
 
a. Study Design 
A retrospective, descriptive study of the distribution and relative frequency of 
neonatal tumours presenting to Chris Hani Baragwanath Academic Hospital 
from 01 January 1988 to 31 December 2012. 
 
b. Study Population 
i.  Inclusion Criteria 
The sample population included all neonates up to 28 days of age who 
were born at or referred to Chris Hani Baragwanath Academic 
Hospital with a malignant or benign tumour. 
 ii.  Exclusion Criteria 
Patients with incomplete data were excluded. 
 
        c.  Procedures 
The clinical records of all patients with neonatal tumours presenting to Chris 
Hani Baragwanath Academic Hospital from 01 January 1988 through to 31 
December 2012 were reviewed.  Patients that presented up to three months of 
age were investigated and if they were symptomatic before 28 days of life they 
were included in the study.  The clinical presentation, pathology, 
demographics, treatment and outcome were identified.  For the purpose of this 
study, tumours were broadly divided into those considered to be malignant 
and those that seemed to be benign. 
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      d.   Data Handling and Collection 
The data was collected and entered onto a prepared data collection sheet.  The 
data sheet captured demographic information, birth and family history, 
classification of tumours, presenting complaints and duration of symptoms, 
any associated factors, treatment received and the outcome of the patients. 
 
e. Data Analysis 
The data was entered into a Microsoft Excel spread sheet.  Appropriate 
descriptive statistical analysis using percentages, means, standard deviations, 
medians and ranges were used. 
 
f. Ethical clearance 
Ethical clearance was obtained from The Human Research Ethics Committee.  
Clearance certificate no. M130257 (See attached). 
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3.0 RESULTS 
 
Over the 24 year period 2626 children (under 19 years of age) were referred to the 
Chris Hani Baragwanath Academic Hospital Oncology Department.  A total of 346 
patients were identified that were three months old and younger.  Out of these, 117 
patients were diagnosed with a malignant or a benign tumour and were symptomatic 
before 28 days of life.  Due to incomplete data 29 patients were excluded.  The study 
included 88 patients; 61 patients (69,3%) were diagnosed with a benign tumour and 
27 patients (30,7%) were diagnosed with a malignant tumour.  (See figure 3 pg 23) 
 
Out of 2626 children referred to the Chris Hani Baragwanath Hospital Oncology 
Department, 2308 were diagnosed with a malignant tumour. (see table 2 pg 20) 
 
Out of 2626 children that presented to Chris Hani Baragwanath Academic Hospital 
Oncology Department, 318 were diagnosed with a benign tumour.  (see table 3 pg 21) 
 
The overall M: F ratio in neonates included in this case series was 1: 1,5; however the 
M: F ratio in the patients diagnosed with a malignant tumour was 1: 0,8.  The mean 
age at presentation was 16 days.  The mean age at diagnosis was 36 days.   In 82% of 
patients the tumours were evident on the first day of life.  The data on stillborn babies 
was not collected.  Although 74% of patients with malignant tumours had symptoms 
at birth, the mean age at presentation to the oncology unit was 15,8 days, and the 
mean age at diagnosis was 39,9 days.  Eight of the patients with a malignant tumour, 
were born at CHBAH, and presented to the oncology unit at a mean age of 10 days, 
with a diagnosis made at a mean age of 43,1 days.   
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Table 2. Distribution and outcome of malignant neonatal and childhood tumours 
Diagnosis Total 
No of 
cases 
No 
occurring 
in 
neonates 
% of 
neonatal 
malignan
cies 
(nr 27) 
% 
presentati
on in 
neonatal 
period 
Mortality 
from 
malignancy 
(No (%)) 
Long-
term 
survivors 
(No (%)) 
Lost 
to 
follow 
up 
(No 
pts) 
Leukaemia 435 4 14,8 0,9 3 (75) 0 1 
CNS tumours 336 1 3,7 0,3 1 (100) 0 0 
Lymphoma 330 0 0 0 0 0 0 
Malignant Soft 
Tissue tumours 
292 7 25,9 2,4 3 (42.9) 3 (42.0) 1 
Retinoblastoma 281 3 11,1 1,1 0 2 (66.7) 1 
Renal tumours 255 5 18,5 2,0 2 (40) 1 (20)* 0 
Neuroblastomas 104 3 11,1 2,9 1 (33.3) 0* 0 
Bone tumours 89 0 0 0 0 0 0 
Hepatic 
tumours 
32 1 3,7 3,1 0 0 1 
Langerhans 
cell 
Histiocytosis 
21 2 7,4 9,5 0 2 (100) 0 
Others 133 1 3,7 0,8 0 1 (100) 0 
Total 2308 27 100 1,2 10 (37) 9 (33.3) 4  
* Four neonates died due to unrelated causes 
 
Of the patients diagnosed with a benign tumour 18 were born at CHBAH.  The mean 
age at presentation to the oncology unit was 8,9 days and the mean age at diagnosis 
was 34,8 days.  The referral time to the oncology unit was 5 days shorter for patients 
with a malignant tumour born at CHBAH.  The age at diagnosis was similar in 
patients born at CHBAH and patients referred from other hospitals.  This delay in 
diagnosing patients can be attributed to a shortage of medical and laboratory staff at 
CHBAH as well as a shortage of laboratory equipment. 
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Table 3. Distribution and outcome of benign neonatal and childhood tumours 
Diagnosis Total 
no of 
cases 
No 
occurring 
in 
neonates 
% of 
benign 
neonatal 
tumours 
(nr 61) 
% 
presentation 
in neonatal 
period 
Mortality 
from 
tumour 
(No (%))  
Long 
term 
survivors  
(No (%)) 
Lost to 
follow 
up (no 
pts) 
Benign vascular 
tumours 
96 27 44,3 28,1 2 (2.4) 13 (48.1) 12 
Teratomas 93 28 45,9 30,1 3 (10.7) 12 (28.6) 12* 
Fibromas 30 2 3,3 6,7 0 0 2 
Lymphangiomas 8 3 4,9 37,5 0 1 (33.3) 2 
Others 91 1 1,6 1,1 0 0 1 
Total 318 61 100 19,2 5 (8.2) 26 (36.1) 29 
* one patient was referred back to the referral hospital.   
 
Histology and radiology were diagnostic in 40,9% and 19,3% respectively.  A 
combination of histology and radiology was used in 21,6% of the diagnoses, 11,4% 
was based on clinical examination and 6,8% on biochemistry and haematology.  
 
Associated syndromes included Klippel Trenauny Weber syndrome, Kasabach-
Merritt syndrome and Down syndrome.  Associated abnormalities included cleft lip, 
ambiguous genitalia, partial aniridia, clubfoot and undescended testes. 
 
A total of 22 neonates received chemotherapy and 50 of the neonates underwent 
surgical resection.  Half of the patients (51,9%) diagnosed with a malignant tumour 
died while 11,1% of patients were lost to follow up.  Death occurred in 8,2% of 
patients diagnosed with a benign tumour died, while 44,3% of patients were lost to 
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follow up. The overall mortality amongst patients diagnosed with benign or malignant 
tumours was 21,6%. 
 
Figure 1.  The distribution of the different malignant conditions in neonates  
 
 
Figure 2.  The distribution of the different benign tumours in neonates 
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Figure 3.   Flow chart of all oncology referrals to CHBAH from 1 Jan 1988 – 31 Dec   
2012 2626	  patients	  presented	  at	  CHBAH	  Oncology	  Department	  
346	  patients	  were	  3	  months	  old	  and	  younger	  
117	  patients	  were	  identified	  with	  neonatal	  tumours	  and	  were	  symptomatic	  before	  28	  days	  
88	  patients	  fulfilled	  inclusion	  criteria	  
29	  patients	  were	  excluded	  due	  to	  incomplete	  data	  
27	  patients	  were	  diagnosed	  with	  a	  malignant	  tumour	   61	  patients	  were	  diagnosed	  with	  a	  benign	  tumour	  
	   	   14	  neonates	  died	  
3	  neonates	  were	  lost	  to	  follow	  up	  
within	  5	  years	  
7	  neonates	  	  were	  alive	  after	  5	  years	  
3	  neonates	  were	  still	  younger	  than	  5	  years	  on	  last	  visit	  
5	  neonates	  died	  
22	  neonates	  	  were	  alive	  after	  5	  years	  
27	  neonates	  were	  lost	  to	  follow	  up	  
within	  5	  years	  
6	  neonates	  were	  still	  younger	  than	  5	  years	  on	  last	  visit,	  1	  sent	  back	  to	  referral	  hospital	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Teratoma 
 
There were 28 neonates diagnosed with teratomas (45,9% of neonatal benign 
tumours) of which 23 were sacrococcygeal.  Of the neonates diagnosed with 
sacrococcygeal teratomas 17 were females, with a M: F ratio of 1: 2,8.  The mean age 
at presentation was 10,6 days.  All of the patients presented with a mass over the 
sacral area or buttocks.  Associations included one patient with ambiguous genitalia, 
one patient with a haemangioma on her left ear, another patient with undescended 
testes and a clubfoot and one patient with abnormal looking thumbs.  All but one 
patient underwent surgical removal. The patient that did not have surgery defaulted 
and was lost to follow up before surgery was performed.  Five neonates received 
chemotherapy due to malignant histology or disease recurrence.  One patient died due 
to disease recurrence. Ten patients were lost to follow up after five years.  The 
mortality rate was 4,3% with the possibility of disease recurrence of 14,8%.  The 
diagnoses were made on histology in 22 neonates.  Alpha Feto Protein was elevated in 
11 patients and radiological investigations were done in all patients to define the 
extent of the tumour for surgery.  Investigations included CT scans and ultrasounds. 
 
Five patients presented with teratomas elsewhere.  Sites included the thyroid gland, 
neck, the pelvis, the brain and the abdomen. Four of the neonates were male and one 
was female. The average age at presentation was 24,2 days.  The first baby with a 
teratoma of the thyroid gland presented with a lateral cystic neck mass, he underwent 
surgical excision; the diagnosis was made on histology and he was sent back to his 
referral hospital.  The next baby was diagnosed with a teratoma of the neck.  He 
presented with a cervical mass, underwent surgical excision; the diagnosis was 
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confirmed on histology but the patient died due to complications of surgery.  The 
third patient presented with acute gastroenteritis and was diagnosed with a teratoma in 
the pelvis based on histology.  He also underwent surgical excision and was 
discharged from oncology.  The fourth patient presented with convulsions and 
hydrocephalus.  He was diagnosed with an intracranial teratoma based on histology 
but died due to disease complications.  The last baby was diagnosed with a teratoma 
in the abdomen.  She presented with abdominal distention and had hydronephrosis 
secondary to compression of the mass on the genitourinary system.  She had surgical 
excision and was discharged at eight years. Two out of the five patients died with a 
mortality of 40%.   
 
Germ-cell tumours 
 
There was one neonate diagnosed with a mixed germ-cell tumour at one month of age 
(3,7% of neonatal malignant tumours).  She was a term neonate born via NVD and 
presented at one week of age with a history of a sacral mass present at birth.  She had 
surgical resection and chemotherapy and the diagnosis was made on histology.  She 
was last seen at 10 months of age and is alive and well. 
 
Benign vascular tumours 
 
Benign vascular tumours were diagnosed in 27 patients (44,3% of neonatal benign 
tumours), of which 22 patients were diagnosed with haemangiomas and five patients 
were diagnosed with haemangioendotheliomas.  Of the 22 patients diagnosed with 
haemangiomas, 14 were female and eight were male patients with a M: F ratio of 1: 
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1,75.  The average age at presentation was 25,1 days.  The diagnosis was based solely 
on clinical examination in nine patients, three patients had biopsies or surgical 
excision, eight patients had symptoms together with radiological features and two 
patients had radiological and histological diagnoses.  The most common site was on 
the extremities followed by the chest and the face.  Associations included Klippel 
Trenauy-Weber syndrome, right heart failure and cleft lip.  Five patients were treated 
medically, three patients underwent surgery and the other remaining patients had no 
treatment.  Two patients died due to unrelated causes.  Eleven patients were 
discharged and nine patients were lost to follow up. 
 
Four out of the five patients with haemangioendotheliomas were females.  The 
average age at presentation was 10,2 days.  Three patients presented with abdominal 
distention and two patients presented with jaundice.  One patient was diagnosed with 
Kasabach-Merritt syndrome and two patients had additional haemangiomas on their 
face and knee respectively.  One patient also had Beckwith Wiedemann syndrome.  
Two patients underwent biopsy and four out of the five patients were treated 
medically.   
 
Malignant Soft Tissue tumours 
 
A total of seven malignant soft tissue tumours were diagnosed (25,9% of neonatal 
malignant tumours).  Six out of the seven patients were males with a M: F ratio of 1: 
0,2.  The average age at presentation was 12,7 days and the average age at diagnoses 
was 51,9 days.  Three out of the seven patients died from disease complications with 
an overall mortality rate of 43%. 
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Table 4.  Patients with malignant soft tissue tumours and their outcome 
Case 
no 
Sex Presenting 
age 
Presenting 
symptoms 
Diagnosis  Treatment Outcome 
1 M 3 days Swelling and 
discoloration 
of right fore 
arm 
Infantile 
fibrosarcoma 
Surgery Discharged 
at 20 years 
2 F 1 day Growth on 
the sole of 
her right foot 
Embryonal 
rhabdomyosarcoma 
Chemotherapy Lost to 
follow up 
but still 
alive* 
 
3 M 21 days Lesion 
below right 
eye 
Alveolar 
rhabdomyosarcoma 
Chemotherapy, 
surgery and 
radiotherapy 
Died at 1 
year due to 
disease 
progression 
4 M 21 days Lump on left 
wrist 
Infantile 
fibrosarcoma 
Surgery Lost to 
follow up 
but is still 
alive* 
5 M 1 day Cystic mass 
on left side 
of chest 
Infantile 
fibrosarcoma 
Chemotherapy, 
surgery and 
radiotherapy 
Died at 13 
months due 
to disease 
progression 
6 M 21 days Lump on 
sole of right 
foot 
Embryonal 
rhabdomyosarcoma 
Chemotherapy, 
surgery and 
radiotherapy 
Defaulted 
for 2 years, 
had 
recurrence, 
then lost to 
follow up 
at 7 years 
7 M 21 days Left 
paranasal 
soft tissue 
mass 
Embryonal 
rhabdomyosarcoma 
Chemotherapy Died at 4 
months due 
to disease 
progression 
*These patients were contacted and although they were lost to follow up at the clinic 
they were alive at the time of analysis. 
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Renal tumours 
 
Five patients were diagnosed with congenital mesoblastic nephromas (18,5% of 
neonatal malignant tumours).  Two were male patients and three were females with a 
M: F ratio of 1: 1,5.  The average age at presentation was four days and the average 
age at diagnosis was 20,6 days.  Four out of the five patients died before the age of 
three years.  One died due to complications of prematurity, another patient died due to 
HIV related complications and two patients died due to disease recurrence.  The 
tumours were inoperable and incompletely resected.  One patient survived and was 
discharged from the clinic at nine years.  
 
Table 5.  Patients with renal tumours and their outcome 
Case 
no 
Sex Presenting 
age 
Presenting 
symptoms 
Associated 
conditions 
/symptoms 
Diagnosis Treatment Outcome 
1 M 4 days Abdominal 
distention 
and left 
flank mass 
SGA CMN Surgery Died at 3 
months from 
complications 
of 
prematurity 
2 F 3 days Right flank 
mass 
HIV 
positive 
CMN Surgery Died at 3 
years from 
complications 
of HIV 
3 M 3 days Right flank 
mass 
Partial 
aniridia 
CMN Surgery Discharged at 
9 years 
4 F 3 days Abdominal 
mass 
HIV 
positive 
CMN Surgery with 
incomplete 
resection 
Died at 2 
years 9 
months 
5 F 7 days Abdominal 
mass 
Nil CMN Surgery and 
chemo-
therapy 
Died at 10 
months due 
to disease 
recurrence 
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Congenital/Neonatal Leukaemia 
 
The clinical information of four patients with suspected congenital leukaemia was 
collected in this case series (14,8% of neonatal malignant tumours).  One patient was 
a confirmed transient myeloid dysplasia.  Three patients presented with acute myeloid 
leukaemia. All the patients were subsequently diagnosed with Down syndrome.  The 
average age at presentation was 6,8 days and the average age at diagnoses was 23,3 
days. 
 
Table 6.  Patients with Congenital/Neonatal leukaemia and their outcome 
Case 
no 
Sex Presenting 
age 
Presenting 
symptoms 
Diagnosis Treatment Outcome 
1 F 10 days Features of Down 
syndrome and a 
raised WCC 
AML Chemotherapy Died at 13 
days 
2 F 7 days Hepatosplenomegally TMD Nil Lost to 
follow up 
at 5 
months 
3 M 5 days Respiratory distress 
and a raised WCC 
AML Nil Died 
4 F 5 days Jaundice and pyrexia AML Chemotherapy Died at 1 
month 
 
 
Neuroblastoma 
 
Three out of the 27 neonates presenting with a malignant tumour were diagnosed with 
neuroblastomas (11,1% of neonatal malignant tumours).   Two patients had stage IV 
disease and one patient stage IVS disease.  All three patients presented within the first 
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week of life with abdominal distention and the diagnoses were confirmed on 
histology. There were two female patients and one male.  The average age at 
presentation was 18 days and the average age at diagnosis was 39,7 days.  All 
received chemotherapy and one patient received chemotherapy and radiotherapy.  All 
three patients died within the first four months of life.  The first two patients died 
from nosocomial sepsis and the third patient died from necrotic bowel secondary to 
abdominal compartment syndrome. 
 
Retinoblastoma 
 
There were three neonates diagnosed with retinoblastomas (11,1% of neonatal 
malignant tumours).  Two patients had bilateral retinoblastomas and one patient had a 
unilateral retinoblastoma.  Two were male patients and one was female patient, with a 
M: F ratio of 1: 0,5.  The average age at presentation was 33,7 days and the average 
age at diagnosis was 34,3 days.  Two patients had incidental findings of café-au-lait 
spots.   
 
Table 7.  Patients with retinoblastoma and their outcome 
Case 
no 
Sex Presenting 
age 
Presenting 
symptoms 
Distribution Treatment Outcome 
1 M 10 days Discharge from eye 
(Brother with RBL) 
Bilateral 
RBL 
Chemotherapy Alive and 
well 
2 M 42 days Leucocoria Unilateral 
RBL 
Surgery Lost to 
follow up 
at 2 years 
3 F 49 days Swelling around eyes Bilateral 
RBL 
Chemotherapy, 
surgery and 
radiotherapy 
Last seen 
at 2 years 
2 months 
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Langerhans cell Histiocytosis 
 
Two patients were identified with LCH (7,4% of neonatal malignant tumours).  The 
average age at presentation was 51 days and the average age at diagnosis was 96 days.  
One was a male patient with a rash over his chest, back and genitalia, that was present 
from the age of one month.  A biopsy confirmed LCH and the patient received 
chemotherapy.  He was discharged at the age of 17 years.  The second patient was a 
female who presented with erythematous papules on her face, body, arms and legs at 
birth.  Histology confirmed LCH and this patient also received chemotherapy.  She 
was last seen at two years six months and was well. 
 
Hepatic tumours 
 
One patient was identified with a congenital hepatoblastoma (3,7% of neonatal 
malignant tumours).  He was a male infant, born at term via NVD and presented with 
an abdominal mass at birth.  A hepatoblastoma was diagnosed on histology, the 
patient underwent surgery and received chemotherapy.  Unfortunately the patient was 
lost to follow up at four and a half years. 
 
Central Nervous System tumours 
 
One patient in this series was diagnosed with a congenital brain tumour (3,7% of 
neonatal malignant tumours). The patient was a male patient, born at term via NVD 
and presented with macrocephaly.  Radiological imaging confirmed hydrocephalus 
secondary to a space occupying lesion and a biopsy confirmed a medulloblastoma.  
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The patient received chemotherapy in a possible attempt to reduce the tumour size.  
Unfortunately the tumour did not respond to chemotherapy and the patient died at 
seven months of age. 
 
Other benign tumours 
 
The remaining benign tumours included three patients with lymphangiomas, two 
patients with fibromas and one patient with a hamartoma (4,9%, 3,3% and 1,6% of 
neonatal benign tumours).  All three of the patients with lymphangiomas were 
females.  The first patient presented with a left axillary mass.  She underwent surgery 
but was lost to follow up.  The second patient presented with a lump in her breast.  
She also underwent surgery but was lost to follow up.  The third patient presented 
with a mass on the right chest wall, that extended anteriorly and posteriorly and down 
to the arm as well.  She underwent surgical excision and was last seen at 16 years of 
age. Both the patients diagnosed with fibromas were males. One patient presented 
with a distal tibial mass, and the second had a right thigh mass.  Both patients 
underwent surgery, and were subsequently lost to follow up. The patient diagnosed 
with a hamartoma presented with congenital pneumonia.  The chest x-ray showed an 
enlarged thymus and a biopsy confirmed a hamartoma.  Unfortunately this patient was 
also lost to follow up. 
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4.0 DISCUSSION  
 
Tumour masses are fairly common findings in the neonatal period but are rarely 
malignant.6   In our series malignant neonatal tumours comprised only 1,2% of all 
childhood malignancies.  This study had a slightly lower incidence than the reported 
2%, which can be attributed to the fact that a large number of tumours are diagnosed 
on post mortem examinations in reported series and not all of the early neonatal 
deaths or stillborn babies undergo post mortem examinations in our institution.4,6  
Unlike other series, we found a female predominance with a M: F ratio of 1: 1,5.  
Most case series report an equal M: F ratio with the exception of teratomas which 
have a strong female predominance.3 When teratomas are excluded, this case series 
still reports a female predominance with a M: F ratio of 1: 1,3.  There was however a 
male predominance in malignant tumours with a M: F ratio of 1: 0,8.  We could not 
identify any race prevalence as almost all patients presenting to Chris Hani 
Baragwanath Academic Hospital were black patients.   
 
As described in the literature, teratomas were the most common tumours diagnosed in 
this case series.  Strong emphasis is placed on strict follow up for the first three years 
of life due to the high risk of disease recurrence early in life.12 Our case series found 
similar results, that all 5 patients with disease recurrence, had recurrences within 3 
years of diagnosis. 
 
The second most common tumours described in neonates are benign vascular tumours 
and this was also found in this case series.  The literature reports it to be four times 
more common in females.  This case series also supported the female predominance 
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but not as strongly as in published data.  Females had a 1,75 times higher risk of a 
benign vascular tumour compared to male patients. Literature also reports benign 
vascular tumours to be more common in premature babies but from the 27 patients 
with benign vascular tumours in our study only two neonates were born prematurely. 
 
The most common malignant tumour in this case series was a malignant soft tissue 
tumour with an incidence of 25,9% of all neonatal malignancies.  This correlates with 
the literature, which reports an incidence of between 10 – 30% of all neonatal 
malignancies.  All three patients with fibrosarcomas were males, in keeping with the 
male predominance reported in the literature.  Studies report a third of all patients 
diagnosed with rhabdomyosarcomas to have at least one congenital anomaly.21  This 
is not supported in our study as all four patients diagnosed with rhabdomyosarcomas 
were otherwise normal.  Half (50%) of the patients diagnosed with 
rhabdomyosarcomas had tumours on the extremities, which is higher than the 
reported 20%.  At CHBAH 1,1% of the patients diagnosed with rhabdomyosarcomas 
were neonates, which is lower than the reported 2%.20 
 
Renal tumours were far more common (18,5%) in this case series than the reported 
4% in literature.6,17  This case series demonstrated a female predominance which 
contradicts the male predominance in the literature.2,24  Patients diagnosed with CMN 
are reported to have an excellent prognosis but in our case series 40% of patients died 
due to disease recurrence attributed to incomplete resection. 
 
There was a higher incidence of congenital leukaemia in this case series with an 
incidence of 14,8% of all neonatal malignancies compared with the 8% reported in 
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literature.6,27  Within the first month of life 75% of patients died and 25% were lost to 
follow up within five months.  This poor prognosis is supported by the literature, 
which reports a 23% two-year survival.27,29 
 
Neuroblastomas were one of the most common tumours present in neonates in many 
of the case series.3,4,5,6,7,34,35  In our study, however, it only comprised 11,1% of all 
neonatal malignancies.  In this case series there was a 100% mortality which 
contradicts the relatively good prognosis in the literature where death due to disease 
was only present in 23 -34% of patients.34,35  However death did not occur solely due 
to the tumour; in two cases it was due to nosocomial sepsis and in the last case the 
patient developed abdominal compartment syndrome and died due to necrosis of the 
intestines. 
 
The incidence of retinoblastoma in this case series was 11,1% of malignant tumours. 
This is much lower than the reported 25% in the Toronto, Canada series. It can be 
attributed to the fact that elective eye examinations are not performed frequently in 
our setting.  Our series supports the higher incidence of bilateral disease similar to 
many studies done in neonates.5,6 
 
Hepatic tumours were as prevalent in our series (3,7%) as the reported 4% in the 
literature reviewed of neonatal tumours.4  The low frequency in the literature is 
supported in our study with only 3,2% of hepatoblastomas diagnosed at CHBAH 
being present in neonates.42 
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We found no evidence of heredity in congenital malignancies, with the exception of 
one case of familial retinoblastoma.  Numerous series reported a clear association 
with certain neonatal tumours and congenital anomalies.  In this series we found 6 
associations including Klippel Trenauny-Weber syndrome and haemangioma, 
Beckwith Weidemann syndrome and haemangioendothelioma and all four leukaemia 
and transient myeloid dysplasia patients were diagnosed with Down syndrome. 
 
Although 82% of patients were symptomatic at birth, the mean age at presentation 
was 16 days and the mean age at diagnosis was 36 days.  Approximately three 
quarters (74%) of patients diagnosed with a malignant tumour were symptomatic at 
birth, with a mean age at presentation of 15,8 days and a mean age of 39,9 days at 
diagnosis. It appears that there is a significant delay in diagnosis, despite relatively 
early referral.  Even though patients born at CHBAH with malignant tumours 
presented earlier to the oncology unit with a mean age at presentation of 10 days, 
there was still a clear delay in diagnosing these infants, with a mean age at diagnosis 
of 43,1 days.  This can be attributed to a shortage of medical laboratory staff as well 
as laboratory services. 
  
In this case series 22 babies received chemotherapy.  Out of this 22, 11 babies died, 
two babies were lost to follow up within five years, five babies are still younger than 
five years of age and four babies were alive and well after 5 years.   A quarter of 
patients (26%) diagnosed with a malignant tumour were alive and well after 5 years 
and 36% of patients with benign tumours were alive and well after 5 years.  The 
documented survival rate in benign tumours may be much higher, as 44% of patients 
were lost to follow up within 5 years. 
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5.0 CONCLUSION 
 
The neonatal period is identified as a time of rapid growth, development and 
maturation of all organs and tissue, especially the brain, liver, kidneys, bones and the 
lungs.  This makes treating a neonate with a malignancy extremely difficult. The 
physician needs to balance treatment that has the best chance for cure, with the risk of 
causing irreversible damage to the rapidly growing organs. 
 
Neonatal tumours are very rare and diagnosing a tumour in a neonate poses many 
difficulties.  It has been shown that neonates diagnosed with a malignant tumour have 
a far better prognosis than cancer diagnosed in older children and a large percentage 
of patients can be successfully treated and cured with little impairment to future well 
being.  At the moment patients present late to the oncology unit and diagnoses are 
delayed due to a shortage of medical staff and staff at laboratory services at public 
hospitals.  People need to be educated and made aware that neonates can be diagnosed 
with tumours. In order to improve the outcome of these patients, 2 major issues need 
to be addressed promptly; timely referral for prompt diagnosis and improved follow-
up of patients.  
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6.0 APPENDICES: DATA COLLECTION SHEET  
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